ClinicalTrials.gg
RecruitingNCT07682298VExUS-AHFUpdated Jul 7, 2026

Assessment of Residual Congestion in Acute Decompensated Heart Failure

An observational study in Acute Heart Failure (AHF) and Decompensated Chronic Heart Failure, sponsored by Aarhus University Hospital. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Aarhus University Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
580
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.

Planned enrollment
14th of 54
580 · median 213
Started
2026
with 11 others
Observational
54 of 242
19 open now
Primary completion
2028-06
later than 35 of 59 live
Registered
239th of 242
by date

Among the 242 studies in Heart Failure with a site in Denmark, this one is the 14th largest by planned enrollment of the 54 observational ones that give a count, is one of 12 that started in 2026, is one of 54 observational ones, reaches primary completion later than 35 of the 59 other live ones, and was the 239th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 242 studies in Heart Failure with a site in Denmark, or all of them as a file.
02

Study summary

DESIGN:

A prospective, multicenter, observational cohort study including 580 patients admitted for acute decompensated heart failure (ADHF).

Ultrasound assessment of congestion (VExUS and LUS) will be performed serially during admission: within 48 hours of admission, at the time diuretic therapy is switched from intravenous to oral, and on the day of discharge. The discharge assessment will serve as the primary predictor.

Treating physicians will be blinded to all ultrasound findings. Patients will be followed for 90 days by telephone follow-up and chart review for the primary endpoint, with extended chart review at one year for selected secondary endpoints.

AIMS:

To determine whether combined ultrasound assessment of venous (VExUS) and pulmonary congestion (LUS) at discharge predicts heart failure readmission and all-cause mortality in patients hospitalized with ADHF.

HYPOTHESIS:

Abnormal VExUS and/or LUS findings at discharge are associated with a higher risk of heart failure readmission and all-cause mortality after 90 days.

03

Conditions studied

  • Acute Heart Failure (AHF)
  • Decompensated Chronic Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Inclusion criteria Age ≥18 years admitted with ADHF, treated with intravenous loop diuretics (≥40 mg furosemide or an equivalent dose of another loop diuretic) during admission, and able to provide written consent will be eligible for inclusion. Clinical evidence of congestion during admission, indicated by ≥1 of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiologic/ultrasound evidence of pulmonary congestion.

Exclusion criteria Pregnancy, moribund, solitary kidney, or inability to provide written consent

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥18 years) admitted with ADHF.
  2. Clinical evidence of congestion during admission, indicated by ≥1 of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiologic/ultrasound evidence of pulmonary congestion.
  3. Treatment with ≥40 mg i.v. furosemide or equivalent dose loop diuretic during admission.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy
  2. Moribund
  3. Solitary kidney
  4. Inability to provide written consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
580 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Groups and cohorts

  • Patients admitted for acute decompensated heart failure
06

What researchers measure

Primary outcomes

  1. Composite of heart failure readmission and all-cause mortality

    Time-to-event analysis. Endpoints appointed by a blinded adjudication committee. Abnormal VExUS will be defined according to criteria from our ongoing validation study. Abnormal LUS is defined as ≥3 B-lines in ≥2 scanning zones per hemithorax (8-zone method) or ≥15 total B-lines overall.

    Time frame: 90 days

Secondary outcomes

  1. Days alive and out of hospital

    Days alive and out of any hospital within 90 days and 1 year, indexed to discharge; death counts as 0 days. Computed over the complete fixed window using chart-based ascertainment of vital status and admissions. Patients censored early for reasons other than death (e.g. withdrawal) are handled by censoring or exclusion (not scored 0, since 0 denotes death). Analyzed with rank-based methods given the zero-spike and skew.

    Time frame: Within 90 days and one year after discharge

  2. Individual components of the primary endpoint

    Time frame: 90 days and one year after discharge

  3. Association between discharge VExUS and markers of congestion

    Markers of congestion: Objective markers (jugular venous pressure, peripheral edema, pulmonary rales, and weight change), NT-proBNP, renal function, and echocardiographic measures of cardiac function.

    Time frame: At discharge

  4. Incremental prognostic value of discharge VExUS and LUS beyond standard clinical assessment of congestion for predicting 90-day and one-year heart-failure readmission and all-cause mortality

    Time frame: 90 days and 1 year

  5. Post-discharge diuretic use

    Defined as the change in loop diuretic dose (furosemide-equivalent) from discharge to 30- and 90-day follow-up, and occurrence of diuretic intensification (dose increase or addition of thiazide-type diuretic) within 90 day

    Time frame: 90 days

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2028, 27 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 27 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartActual
Feb 15, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Nov 1, 2028
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07682298
Collaborators
Zealand University Hospital, Amager Hospital
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Feb 15, 2026
Primary completion
Jun 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

Kristoffer Berg-Hansen, MD, PhD
Contact
krisbe@rm.dk
+4560540700

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion